{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:46:47Z","timestamp":1784288807806,"version":"3.55.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["AI164561"],"award-info":[{"award-number":["AI164561"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["AI164556"],"award-info":[{"award-number":["AI164556"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["MH130178"],"award-info":[{"award-number":["MH130178"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HL156274"],"award-info":[{"award-number":["HL156274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-024-01240-4","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T06:02:25Z","timestamp":1721628145000},"page":"1700-1714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Reprogramming human B cells with custom heavy-chain antibodies"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-1269","authenticated-orcid":false,"given":"Geoffrey L.","family":"Rogers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6872-944X","authenticated-orcid":false,"given":"Atishay","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalya","family":"Stanten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidy","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Hua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Kezirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0059-354X","authenticated-orcid":false,"given":"Paula M.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"1240_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-chembioeng-101121-084508","volume":"14","author":"AN Qerqez","year":"2023","unstructured":"Qerqez, A. N., Silva, R. P. & Maynard, J. A. Outsmarting pathogens with antibody engineering. Annu. Rev. Chem. Biomol. Eng. 14, 217\u2013241 (2023).","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"1240_CR2","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","volume":"185","author":"PJ Carter","year":"2022","unstructured":"Carter, P. J. & Rajpal, A. Designing antibodies as therapeutics. Cell 185, 2789\u20132805 (2022).","journal-title":"Cell"},{"key":"1240_CR3","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/cancers12040962","volume":"12","author":"A Page","year":"2020","unstructured":"Page, A., Fusil, F. & Cosset, F. L. Towards physiologically and tightly regulated vectored antibody therapies. Cancers 12, 962 (2020).","journal-title":"Cancers"},{"key":"1240_CR4","doi-asserted-by":"publisher","first-page":"673699","DOI":"10.3389\/fimmu.2021.673699","volume":"12","author":"W Zhan","year":"2021","unstructured":"Zhan, W., Muhuri, M., Tai, P. W. L. & Gao, G. Vectored immunotherapeutics for infectious diseases: can rAAVs be the game changers for fighting transmissible pathogens? Front. Immunol. 12, 673699 (2021).","journal-title":"Front. Immunol."},{"key":"1240_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fimmu.2020.00449","volume":"11","author":"JM Martinez-Navio","year":"2020","unstructured":"Martinez-Navio, J. M. et al. Long-term delivery of an anti-SIV monoclonal antibody with AAV. Front. Immunol. 11, 449 (2020).","journal-title":"Front. Immunol."},{"key":"1240_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ymthe.2019.01.004","volume":"27","author":"MR Gardner","year":"2019","unstructured":"Gardner, M. R. et al. Anti-drug antibody responses impair prophylaxis mediated by AAV-delivered HIV-1 broadly neutralizing antibodies. Mol. Ther. 27, 650\u2013660 (2019).","journal-title":"Mol. Ther."},{"key":"1240_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.omtm.2019.11.010","volume":"16","author":"SP Fuchs","year":"2020","unstructured":"Fuchs, S. P., Martinez-Navio, J. M., Rakasz, E. G., Gao, G. & Desrosiers, R. C. Liver-directed but not muscle-directed AAV-antibody gene transfer limits humoral immune responses in rhesus monkeys. Mol. Ther. Methods Clin. Dev. 16, 94\u2013102 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1240_CR8","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","volume":"6","author":"FH Priddy","year":"2019","unstructured":"Priddy, F. H. et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV 6, e230\u2013e239 (2019).","journal-title":"Lancet HIV"},{"key":"1240_CR9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","volume":"28","author":"JP Casazza","year":"2022","unstructured":"Casazza, J. P. et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat. Med. 28, 1022\u20131030 (2022).","journal-title":"Nat. Med."},{"key":"1240_CR10","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1016\/j.ymthe.2021.09.019","volume":"29","author":"GL Rogers","year":"2021","unstructured":"Rogers, G. L. & Cannon, P. M. Genome edited B cells: a new frontier in immune cell therapies. Mol. Ther. 29, 3192\u20133204 (2021).","journal-title":"Mol. Ther."},{"key":"1240_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19649-1","volume":"11","author":"AD Nahmad","year":"2020","unstructured":"Nahmad, A. D. et al. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nat. Commun. 11, 5851 (2020).","journal-title":"Nat. Commun."},{"key":"1240_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19650-8","volume":"11","author":"D Huang","year":"2020","unstructured":"Huang, D. et al. Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. Nat. Commun. 11, 5850 (2020).","journal-title":"Nat. Commun."},{"key":"1240_CR13","doi-asserted-by":"publisher","first-page":"eaax0644","DOI":"10.1126\/sciimmunol.aax0644","volume":"4","author":"HF Moffett","year":"2019","unstructured":"Moffett, H. F. et al. B cells engineered to express pathogen-specific antibodies protect against infection. Sci Immunol 4, eaax0644 (2019).","journal-title":"Sci Immunol"},{"key":"1240_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1084\/jem.20190287","volume":"216","author":"H Hartweger","year":"2019","unstructured":"Hartweger, H. et al. HIV-specific humoral immune responses by CRISPR\/Cas9-edited B cells. J. Exp. Med. 216, 1301\u20131310 (2019).","journal-title":"J. Exp. Med."},{"key":"1240_CR15","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41587-022-01328-9","volume":"40","author":"AD Nahmad","year":"2022","unstructured":"Nahmad, A. D. et al. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat. Biotechnol. 40, 1241\u20131249 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1240_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ymthe.2021.10.027","volume":"30","author":"T Ou","year":"2022","unstructured":"Ou, T. et al. Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire. Mol. Ther. 30, 184\u2013197 (2022).","journal-title":"Mol. Ther."},{"key":"1240_CR17","doi-asserted-by":"publisher","first-page":"e42995","DOI":"10.7554\/eLife.42995","volume":"8","author":"JE Voss","year":"2019","unstructured":"Voss, J. E. et al. Reprogramming the antigen specificity of B cells using genome-editing technologies. eLife 8, e42995 (2019).","journal-title":"eLife"},{"key":"1240_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.isci.2019.01.032","volume":"12","author":"V Greiner","year":"2019","unstructured":"Greiner, V. et al. CRISPR-mediated editing of the B cell receptor in primary human B cells. iScience 12, 369\u2013378 (2019).","journal-title":"iScience"},{"key":"1240_CR19","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","volume":"10","author":"KO Saunders","year":"2019","unstructured":"Saunders, K. O. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 10, 1296 (2019).","journal-title":"Front. Immunol."},{"key":"1240_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-bioeng-082721-024500","volume":"24","author":"G Delidakis","year":"2022","unstructured":"Delidakis, G., Kim, J. E., George, K. & Georgiou, G. Improving antibody therapeutics by manipulating the Fc domain: immunological and structural considerations. Annu. Rev. Biomed. Eng. 24, 249\u2013274 (2022).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"1240_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775\u2013797 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"1240_CR22","doi-asserted-by":"publisher","first-page":"114726","DOI":"10.1016\/j.addr.2023.114726","volume":"195","author":"J Yong Joon Kim","year":"2023","unstructured":"Yong Joon Kim, J., Sang, Z., Xiang, Y., Shen, Z. & Shi, Y. Nanobodies: robust miniprotein binders in biomedicine. Adv. Drug Deliv. Rev. 195, 114726 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1240_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/wrna.36","volume":"2","author":"ML Peterson","year":"2011","unstructured":"Peterson, M. L. Immunoglobulin heavy chain gene regulation through polyadenylation and splicing competition. Wiley Interdiscip. Rev. RNA 2, 92\u2013105 (2011).","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"1240_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.20112655","volume":"209","author":"LE McCoy","year":"2012","unstructured":"McCoy, L. E. et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 209, 1091\u20131103 (2012).","journal-title":"J. Exp. Med."},{"key":"1240_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08273-7","volume":"7","author":"K Koch","year":"2017","unstructured":"Koch, K. et al. Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers. Sci. Rep. 7, 8390 (2017).","journal-title":"Sci. Rep."},{"key":"1240_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/eji.1830100305","volume":"10","author":"PA Singer","year":"1980","unstructured":"Singer, P. A. & Williamson, A. R. Cell surface immunoglobulin \u03bc and \u03b3 chains of human lymphoid cells are of higher apparent molecular weight than their secreted counterparts. Eur. J. Immunol. 10, 180\u2013186 (1980).","journal-title":"Eur. J. Immunol."},{"key":"1240_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4049\/jimmunol.160.2.595","volume":"160","author":"GS Ford","year":"1998","unstructured":"Ford, G. S., Yin, C. H., Barnhart, B., Sztam, K. & Covey, L. R. CD40 ligand exerts differential effects on the expression of I\u03b3 transcripts in subclones of an IgM+ human B cell lymphoma line. J. Immunol. 160, 595\u2013605 (1998).","journal-title":"J. Immunol."},{"key":"1240_CR28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.str.2022.03.012","volume":"30","author":"T Zhou","year":"2022","unstructured":"Zhou, T. et al. Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. Structure 30, 862\u2013875 (2022).","journal-title":"Structure"},{"key":"1240_CR29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2008-09-177139","volume":"113","author":"XM Luo","year":"2009","unstructured":"Luo, X. M. et al. Engineering human hematopoietic stem\/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113, 1422\u20131431 (2009).","journal-title":"Blood"},{"key":"1240_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0065-2776(10)05006-6","volume":"105","author":"RW Maul","year":"2010","unstructured":"Maul, R. W. & Gearhart, P. J. AID and somatic hypermutation. Adv. Immunol. 105, 159\u2013191 (2010).","journal-title":"Adv. Immunol."},{"key":"1240_CR31","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.molimm.2005.09.011","volume":"43","author":"F Ruckerl","year":"2006","unstructured":"Ruckerl, F., Busse, B. & Bachl, J. Episomal vectors to monitor and induce somatic hypermutation in human Burkitt-lymphoma cell lines. Mol. Immunol. 43, 1645\u20131652 (2006).","journal-title":"Mol. Immunol."},{"key":"1240_CR32","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B. J. & Wine, Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front. Immunol. 11, 1951 (2020).","journal-title":"Front. Immunol."},{"key":"1240_CR33","doi-asserted-by":"publisher","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","volume":"14","author":"YZ Cohen","year":"2019","unstructured":"Cohen, Y. Z. et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study. PLoS ONE 14, e0219142 (2019).","journal-title":"PLoS ONE"},{"key":"1240_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00332-6","volume":"9","author":"Y Asaadi","year":"2021","unstructured":"Asaadi, Y., Jouneghani, F. F., Janani, S. & Rahbarizadeh, F. A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomark. Res. 9, 87 (2021).","journal-title":"Biomark. Res."},{"key":"1240_CR35","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1074\/jbc.M806889200","volume":"284","author":"C Vincke","year":"2009","unstructured":"Vincke, C. et al. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284, 3273\u20133284 (2009).","journal-title":"J. Biol. Chem."},{"key":"1240_CR36","doi-asserted-by":"publisher","first-page":"gzab012","DOI":"10.1093\/protein\/gzab012","volume":"34","author":"K Belanger","year":"2021","unstructured":"Belanger, K. & Tanha, J. High-efficacy, high-manufacturability human VH domain antibody therapeutics from transgenic sources. Protein Eng. Des. Sel. 34, gzab012 (2021).","journal-title":"Protein Eng. Des. Sel."},{"key":"1240_CR37","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.dnarep.2006.05.022","volume":"5","author":"E Sonoda","year":"2006","unstructured":"Sonoda, E., Hochegger, H., Saberi, A., Taniguchi, Y. & Takeda, S. Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair 5, 1021\u20131029 (2006).","journal-title":"DNA Repair"},{"key":"1240_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2021.09.003","volume":"23","author":"GL Rogers","year":"2021","unstructured":"Rogers, G. L. et al. Optimization of AAV6 transduction enhances site-specific genome editing of primary human lymphocytes. Mol. Ther. Methods Clin. Dev. 23, 198\u2013209 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1240_CR39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymthe.2017.11.012","volume":"26","author":"KL Hung","year":"2018","unstructured":"Hung, K. L. et al. Engineering protein-secreting plasma cells by homology-directed repair in primary human B cells. Mol. Ther. 26, 456\u2013467 (2018).","journal-title":"Mol. Ther."},{"key":"1240_CR40","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","volume":"10","author":"I Sanz","year":"2019","unstructured":"Sanz, I. et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front. Immunol. 10, 2458 (2019).","journal-title":"Front. Immunol."},{"key":"1240_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","volume":"24","author":"G Schiroli","year":"2019","unstructured":"Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell 24, 551\u2013565 (2019).","journal-title":"Cell Stem Cell"},{"key":"1240_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1600-065X.2010.00935.x","volume":"237","author":"C Vettermann","year":"2010","unstructured":"Vettermann, C. & Schlissel, M. S. Allelic exclusion of immunoglobulin genes: models and mechanisms. Immunol. Rev. 237, 22\u201342 (2010).","journal-title":"Immunol. Rev."},{"key":"1240_CR43","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1084\/jem.20131539","volume":"210","author":"JS He","year":"2013","unstructured":"He, J. S. et al. The distinctive germinal center phase of IgE+ B lymphocytes limits their contribution to the classical memory response. J. Exp. Med. 210, 2755\u20132771 (2013).","journal-title":"J. Exp. Med."},{"key":"1240_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-020-01145-0","volume":"27","author":"LE Wagar","year":"2021","unstructured":"Wagar, L. E. et al. Modeling human adaptive immune responses with tonsil organoids. Nat. Med. 27, 125\u2013135 (2021).","journal-title":"Nat. Med."},{"key":"1240_CR45","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.immuni.2023.06.019","volume":"56","author":"JM Kastenschmidt","year":"2023","unstructured":"Kastenschmidt, J. M. et al. Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. Immunity 56, 1910\u20131926 (2023).","journal-title":"Immunity"},{"key":"1240_CR46","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1128\/JVI.02566-13","volume":"88","author":"W Chen","year":"2014","unstructured":"Chen, W. et al. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J. Virol. 88, 1125\u20131139 (2014).","journal-title":"J. Virol."},{"key":"1240_CR47","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature10373","volume":"477","author":"LM Walker","year":"2011","unstructured":"Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466\u2013470 (2011).","journal-title":"Nature"},{"key":"1240_CR48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/antib8020028","volume":"8","author":"A Bates","year":"2019","unstructured":"Bates, A. & Power, C. A. David vs. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies 8, 28 (2019).","journal-title":"Antibodies"},{"key":"1240_CR49","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","volume":"28","author":"AV Finck","year":"2022","unstructured":"Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G. & June, C. H. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 28, 678\u2013689 (2022).","journal-title":"Nat. Med."},{"key":"1240_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/eji.1830160206","volume":"16","author":"T Hibi","year":"1986","unstructured":"Hibi, T. & Dosch, H. M. Limiting dilution analysis of the B cell compartment in human bone marrow. Eur. J. Immunol. 16, 139\u2013145 (1986).","journal-title":"Eur. J. Immunol."},{"key":"1240_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01901-w","volume":"8","author":"E Hammarlund","year":"2017","unstructured":"Hammarlund, E. et al. Plasma cell survival in the absence of B cell memory. Nat. Commun. 8, 1781 (2017).","journal-title":"Nat. Commun."},{"key":"1240_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33787-8","volume":"13","author":"RY Cheng","year":"2022","unstructured":"Cheng, R. Y. et al. Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo. Nat. Commun. 13, 6110 (2022).","journal-title":"Nat. Commun."},{"key":"1240_CR53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aaz8432","volume":"370","author":"CW Davis","year":"2020","unstructured":"Davis, C. W. et al. Influenza vaccine-induced human bone marrow plasma cells decline within a year after vaccination. Science 370, 237\u2013241 (2020).","journal-title":"Science"},{"key":"1240_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1066123","volume":"14","author":"WO Monzon-Posadas","year":"2023","unstructured":"Monzon-Posadas, W. O. et al. Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2. Front. Immunol. 14, 1066123 (2023).","journal-title":"Front. Immunol."},{"key":"1240_CR55","doi-asserted-by":"publisher","first-page":"e44245","DOI":"10.7554\/eLife.44245","volume":"8","author":"T Koike","year":"2019","unstructured":"Koike, T., Harada, K., Horiuchi, S. & Kitamura, D. The quantity of CD40 signaling determines the differentiation of B cells into functionally distinct memory cell subsets. eLife 8, e44245 (2019).","journal-title":"eLife"},{"key":"1240_CR56","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1080\/19420862.2019.1640549","volume":"11","author":"KK Joshi","year":"2019","unstructured":"Joshi, K. K. et al. Elucidating heavy\/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells. mAbs 11, 1254\u20131265 (2019).","journal-title":"mAbs"},{"key":"1240_CR57","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","volume":"24","author":"BK Jin","year":"2023","unstructured":"Jin, B. K., Odongo, S., Radwanska, M. & Magez, S. NANOBODIES\u00ae: a review of generation, diagnostics and therapeutics. Int. J. Mol. Sci. 24, 5994 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1240_CR58","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446\u2013448 (1993).","journal-title":"Nature"},{"key":"1240_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1042\/BA20090208","volume":"54","author":"MR Blanc","year":"2009","unstructured":"Blanc, M. R. et al. A one-step exclusion-binding procedure for the purification of functional heavy-chain and mammalian-type gamma-globulins from camelid sera. Biotechnol. Appl. Biochem. 54, 207\u2013212 (2009).","journal-title":"Biotechnol. Appl. Biochem."},{"key":"1240_CR60","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1128\/CVI.00287-10","volume":"17","author":"LP Daley-Bauer","year":"2010","unstructured":"Daley-Bauer, L. P. et al. Contributions of conventional and heavy-chain IgG to immunity in fetal, neonatal, and adult alpacas. Clin. Vaccine Immunol. 17, 2007\u20132015 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"1240_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00684-23","volume":"97","author":"GN Llewellyn","year":"2023","unstructured":"Llewellyn, G. N. et al. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides. J. Virol. 97, e0068423 (2023).","journal-title":"J. Virol."},{"key":"1240_CR62","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","volume":"362","author":"NS Laursen","year":"2018","unstructured":"Laursen, N. S. et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science 362, 598\u2013602 (2018).","journal-title":"Science"},{"key":"1240_CR63","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1073\/pnas.1203954109","volume":"109","author":"P Smith","year":"2012","unstructured":"Smith, P., DiLillo, D. J., Bournazos, S., Li, F. & Ravetch, J. V. Mouse model recapitulating human Fc\u03b3 receptor structural and functional diversity. Proc. Natl Acad. Sci. USA 109, 6181\u20136186 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1240_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157\u2013159 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1240_CR65","doi-asserted-by":"publisher","first-page":"17885","DOI":"10.1074\/jbc.M116.771188","volume":"292","author":"J Yu","year":"2017","unstructured":"Yu, J. et al. A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line. J. Biol. Chem. 292, 17885\u201317896 (2017).","journal-title":"J. Biol. Chem."},{"key":"1240_CR66","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.omtm.2023.02.004","volume":"28","author":"E Vamva","year":"2023","unstructured":"Vamva, E. et al. A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin. Mol. Ther. Methods Clin. Dev. 28, 366\u2013384 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1240_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade2798","volume":"8","author":"P Irrgang","year":"2023","unstructured":"Irrgang, P. et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 8, eade2798 (2023).","journal-title":"Sci. Immunol."},{"key":"1240_CR68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.immuni.2019.07.001","volume":"51","author":"JA Roco","year":"2019","unstructured":"Roco, J. A. et al. Class-switch recombination occurs infrequently in germinal centers. Immunity 51, 337\u2013350 (2019).","journal-title":"Immunity"},{"key":"1240_CR69","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.1086907","volume":"301","author":"H Wardemann","year":"2003","unstructured":"Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374\u20131377 (2003).","journal-title":"Science"},{"key":"1240_CR70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1084\/jem.20061918","volume":"204","author":"R Casellas","year":"2007","unstructured":"Casellas, R. et al. Ig\u03ba allelic inclusion is a consequence of receptor editing. J. Exp. Med. 204, 153\u2013160 (2007).","journal-title":"J. Exp. Med."},{"key":"1240_CR71","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.coi.2014.01.012","volume":"27","author":"R Pelanda","year":"2014","unstructured":"Pelanda, R. Dual immunoglobulin light chain B cells: Trojan horses of autoimmunity? Curr. Opin. Immunol. 27, 53\u201359 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"1240_CR72","doi-asserted-by":"publisher","first-page":"7747","DOI":"10.1073\/pnas.0509121103","volume":"103","author":"C Sirac","year":"2006","unstructured":"Sirac, C., Carrion, C., Duchez, S., Comte, I. & Cogne, M. Light chain inclusion permits terminal B cell differentiation and does not necessarily result in autoreactivity. Proc. Natl Acad. Sci. USA 103, 7747\u20137752 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1240_CR73","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4049\/jimmunol.179.2.1049","volume":"179","author":"MG Velez","year":"2007","unstructured":"Velez, M. G. et al. Ig allotypic inclusion does not prevent B cell development or response. J. Immunol. 179, 1049\u20131057 (2007).","journal-title":"J. Immunol."},{"key":"1240_CR74","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.4049\/jimmunol.1202331","volume":"190","author":"E Makdasi","year":"2013","unstructured":"Makdasi, E. & Eilat, D. L chain allelic inclusion does not increase autoreactivity in lupus-prone New Zealand Black\/New Zealand White mice. J. Immunol. 190, 1472\u20131480 (2013).","journal-title":"J. Immunol."},{"key":"1240_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795209","volume":"13","author":"JN Peterson","year":"2022","unstructured":"Peterson, J. N. et al. Elevated detection of dual antibody B cells identifies lupus patients with B cell-reactive VH4-34 autoantibodies. Front. Immunol. 13, 795209 (2022).","journal-title":"Front. Immunol."},{"key":"1240_CR76","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.ymthe.2019.08.019","volume":"27","author":"GL Rogers","year":"2019","unstructured":"Rogers, G. L., Chen, H. Y., Morales, H. & Cannon, P. M. Homologous recombination-based genome editing by clade F AAVs is inefficient in the absence of a targeted DNA break. Mol. Ther. 27, 1726\u20131736 (2019).","journal-title":"Mol. Ther."},{"key":"1240_CR77","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1089\/hum.2009.223","volume":"21","author":"M Lock","year":"2010","unstructured":"Lock, M. et al. Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum. Gene Ther. 21, 1273\u20131285 (2010).","journal-title":"Hum. Gene Ther."},{"key":"1240_CR78","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000369273","volume":"7","author":"GL Rogers","year":"2015","unstructured":"Rogers, G. L. et al. Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer. J. Innate Immun. 7, 302\u2013314 (2015).","journal-title":"J. Innate Immun."},{"key":"1240_CR79","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.ymthe.2020.10.006","volume":"29","author":"KJ Tatiossian","year":"2021","unstructured":"Tatiossian, K. J. et al. Rational selection of CRISPR\u2013Cas9 guide RNAs for homology-directed genome editing. Mol. Ther. 29, 1057\u20131069 (2021).","journal-title":"Mol. Ther."},{"key":"1240_CR80","doi-asserted-by":"publisher","first-page":"e02086-18","DOI":"10.1128\/JVI.02086-18","volume":"93","author":"GN Llewellyn","year":"2019","unstructured":"Llewellyn, G. N. et al. Humanized mouse model of HIV-1 latency with enrichment of latent virus in PD-1+ and TIGIT+ CD4 T cells. J. Virol. 93, e02086-18 (2019).","journal-title":"J. Virol."},{"key":"1240_CR81","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"1240_CR82","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/nprot.2008.133","volume":"3","author":"DJ Korbie","year":"2008","unstructured":"Korbie, D. J. & Mattick, J. S. Touchdown PCR for increased specificity and sensitivity in PCR amplification. Nat. Protoc. 3, 1452\u20131456 (2008).","journal-title":"Nat. Protoc."},{"key":"1240_CR83","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/crispr.2021.0113","volume":"5","author":"D Conant","year":"2022","unstructured":"Conant, D. et al. Inference of CRISPR edits from Sanger trace data. CRISPR J. 5, 123\u2013130 (2022).","journal-title":"CRISPR J."},{"key":"1240_CR84","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/dvdy.24183","volume":"243","author":"JT Hill","year":"2014","unstructured":"Hill, J. T. et al. Poly peak parser: method and software for identification of unknown indels using sanger sequencing of polymerase chain reaction products. Dev. Dyn. 243, 1632\u20131636 (2014).","journal-title":"Dev. Dyn."},{"key":"1240_CR85","doi-asserted-by":"publisher","first-page":"20130624","DOI":"10.1098\/rstb.2013.0624","volume":"370","author":"N Rohland","year":"2015","unstructured":"Rohland, N., Harney, E., Mallick, S., Nordenfelt, S. & Reich, D. Partial uracil-DNA-glycosylase treatment for screening of ancient DNA. Philos. Trans. R Soc. Lond B 370, 20130624 (2015).","journal-title":"Philos. Trans. R Soc. Lond B"},{"key":"1240_CR86","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2105-13-31","volume":"13","author":"AP Masella","year":"2012","unstructured":"Masella, A. P., Bartram, A. K., Truszkowski, J. M., Brown, D. G. & Neufeld, J. D. PANDAseq: paired-end assembler for illumina sequences. BMC Bioinform. 13, 31 (2012).","journal-title":"BMC Bioinform."},{"key":"1240_CR87","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1093\/bioinformatics\/btp450","volume":"25","author":"M Morgan","year":"2009","unstructured":"Morgan, M. et al. ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data. Bioinformatics 25, 2607\u20132608 (2009).","journal-title":"Bioinformatics"},{"key":"1240_CR88","unstructured":"Pag\u00e8s, H., Aboyoun, P., Gentleman, R. & DebRoy, S. Biostrings: efficient manipulation of biological strings. R package version 2.62.0 https:\/\/bioconductor.org\/packages\/Biostrings (2021)."},{"key":"1240_CR89","unstructured":"Schauberger, P. & Walker, A. openxlsx: read, write and edit xlsx files. R package version 4.2.5.1 https:\/\/CRAN.R-project.org\/package=openxlsx (2022)."},{"key":"1240_CR90","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/1755-0998.13294","volume":"21","author":"B Fields","year":"2021","unstructured":"Fields, B., Moeskjaer, S., Friman, V. P., Andersen, S. U. & Young, J. P. W. MAUI-seq: metabarcoding using amplicons with unique molecular identifiers to improve error correction. Mol. Ecol. Resour. 21, 703\u2013720 (2021).","journal-title":"Mol. Ecol. Resour."},{"key":"1240_CR91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41592-020-01041-y","volume":"18","author":"SM Karst","year":"2021","unstructured":"Karst, S. M. et al. High-accuracy long-read amplicon sequences using unique molecular identifiers with Nanopore or PacBio sequencing. Nat. Methods 18, 165\u2013169 (2021).","journal-title":"Nat. Methods"},{"key":"1240_CR92","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.4049\/jimmunol.172.6.3382","volume":"172","author":"IB Rogozin","year":"2004","unstructured":"Rogozin, I. B. & Diaz, M. Cutting edge: DGYW\/WRCH is a better predictor of mutability at G:C bases in Ig hypermutation than the widely accepted RGYW\/WRCY motif and probably reflects a two-step activation-induced cytidine deaminase-triggered process. J. Immunol. 172, 3382\u20133384 (2004).","journal-title":"J. Immunol."},{"key":"1240_CR93","unstructured":"Wagih, O. ggseqlogo: A \u2018ggplot2\u2019 extension for drawing publication-ready sequence logos. R package version 0.1 https:\/\/CRAN.R-project.org\/package=ggseqlogo (2017)."},{"key":"1240_CR94","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jmb.2007.02.100","volume":"369","author":"KR Abhinandan","year":"2007","unstructured":"Abhinandan, K. R. & Martin, A. C. Analyzing the \u2018degree of humanness\u2019 of antibody sequences. J. Mol. Biol. 369, 852\u2013862 (2007).","journal-title":"J. Mol. Biol."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01240-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T13:02:57Z","timestamp":1735045377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01240-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":94,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1038\/s41551-024-01240-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.06.28.546944","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-3117686\/v1","asserted-by":"object"}]},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}